Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis
Acta Neurologica Belgica · 2024-04 · 124 (2) · 407-417
DOI: 10.1007/s13760-024-02480-6 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Acta Neurologica Belgica, online erschienen am 08.03.2024. Verfasst von Eslam Mohammed Rabea und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Alexandria University, Alexandria, Egypt. Hauptthemen laut MEDLINE: Natalizumab, Multiple Sclerosis, Immunologic Factors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Azhar University.
Abstract (Originalsprache)
Background
Multiple sclerosis (MS) is a chronic inflammatory, immune-mediated disease affecting the central nervous system. Natalizumab, an FDA-approved monoclonal antibody for MS, has been explored for its off-label extended interval dosing (EID), suggesting a potential reduction in the risk of progressive multifocal leukoencephalopathy (PML) compared to standard interval dosing (SID). Our objective was to assess the efficacy and safety of EID in comparison to SID for natalizumab treatment in patients with MS.
Methods
We searched PubMed, Embase, WOS, Scopus, Ovid, Science Direct, Clinical trials.gov, and Cochrane Library. Our assessed outcomes were clinical relapses, MRI activity, change in expanded disability status scale [EDSS], and the risk of PML. The EID group was defined as 5 to 8 weeks [EID (Q5-8W)]. The analysis was conducted using RevMan ver. 5.4. The effect estimates were presented as a risk ratio [RR] or mean difference with 95% confidence intervals [CI] using SID group as the reference for comparisons.
Results
Fourteen studies met our inclusion criteria: 2 RCTs, 1 switched single-arm trial, and 12 observational studies. No significant differences were found in all efficacy outcomes of interest. Risk of clinical relapses [RR = 0.90, (95%CI 0.80, 1.02)], risk of new or newly enlarging T2 hyperintense MRI lesions [RR = 0.78, (95%CI 0.59, 1.04)], risk gadolinium enhancing lesions [RR = 1.30, (95%CI 0.98, 1.72)], change in EDSS [MD = 0.09 (95%CI − 0.57, 0.76)], risk of PML [RR = 1.09, 95%CI (0.24, 4.94)].
Conclusion
In summary, our meta-analysis indicates that natalizumab maintains its effectiveness under extended interval dosing [up to 8 weeks], presenting comparable risks for clinical relapses, MRI lesions, EDSS, and PML. Caution is advised given study limitations and heterogeneity. Robust conclusions necessitate well-designed high-quality prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Faculty of Medicine, Al-Azhar University, Assiut, Egypt. MohamedZaazouee.stu.6.44@azhar.edu.eg.
Förderung
- Al-Azhar University
Zitieren
APA
Rabea, E. M., Belal, M. M., Hafez, A. H., Elbanna, A. H., Khalifa, M. A., Nourelden, A. Z., Mahmoud, N. H., & Zaazouee, M. S. (2024). Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis. Acta Neurologica Belgica, 124(2), 407-417. https://doi.org/10.1007/s13760-024-02480-6
Vancouver
Rabea EM, Belal MM, Hafez AH, Elbanna AH, Khalifa MA, Nourelden AZ, et al. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis. Acta Neurologica Belgica. 2024;124(2):407-417. doi:10.1007/s13760-024-02480-6
BibTeX
@article{Rabea2024,
author = {Rabea, Eslam Mohammed and Belal, Mohamed Mohamed and Hafez, Abdelrahman H and Elbanna, Ashraf Hassan and Khalifa, Mahmoud Ahmed and Nourelden, Anas Zakarya and Mahmoud, Nada H and Zaazouee, Mohamed Sayed},
title = {Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis},
journal = {Acta Neurologica Belgica},
year = {2024},
volume = {124},
number = {2},
pages = {407--417},
doi = {10.1007/s13760-024-02480-6}
}
EUVIMED